BioLife Solutions, Inc. (NASDAQ:BLFS - Get Free Report) EVP Aby J. Mathew sold 521 shares of the company's stock in a transaction dated Wednesday, May 28th. The shares were sold at an average price of $22.46, for a total value of $11,701.66. Following the sale, the executive vice president now owns 308,486 shares in the company, valued at approximately $6,928,595.56. This represents a 0.17% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.
BioLife Solutions Trading Down 2.2%
Shares of NASDAQ:BLFS opened at $21.83 on Friday. The stock has a market capitalization of $1.04 billion, a price-to-earnings ratio of -20.59 and a beta of 2.01. The company has a debt-to-equity ratio of 0.03, a quick ratio of 1.78 and a current ratio of 2.78. The stock's 50-day simple moving average is $22.86 and its two-hundred day simple moving average is $25.06. BioLife Solutions, Inc. has a 52-week low of $18.70 and a 52-week high of $29.55.
BioLife Solutions (NASDAQ:BLFS - Get Free Report) last posted its quarterly earnings data on Thursday, May 8th. The medical equipment provider reported $0.04 earnings per share for the quarter, beating analysts' consensus estimates of ($0.03) by $0.07. BioLife Solutions had a negative return on equity of 6.61% and a negative net margin of 38.98%. The firm had revenue of $23.94 million for the quarter, compared to analysts' expectations of $22.22 million. Analysts expect that BioLife Solutions, Inc. will post -0.3 EPS for the current year.
Wall Street Analyst Weigh In
Several brokerages have issued reports on BLFS. HC Wainwright reaffirmed a "buy" rating and issued a $30.00 target price on shares of BioLife Solutions in a research note on Tuesday, May 13th. Wall Street Zen lowered BioLife Solutions from a "hold" rating to a "sell" rating in a research note on Wednesday, May 21st. One research analyst has rated the stock with a sell rating and six have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $31.17.
Get Our Latest Report on BioLife Solutions
Institutional Trading of BioLife Solutions
A number of large investors have recently added to or reduced their stakes in the company. D.A. Davidson & CO. increased its stake in BioLife Solutions by 1.3% in the 4th quarter. D.A. Davidson & CO. now owns 41,179 shares of the medical equipment provider's stock worth $1,069,000 after acquiring an additional 519 shares during the last quarter. Sei Investments Co. increased its stake in BioLife Solutions by 0.5% in the 1st quarter. Sei Investments Co. now owns 117,999 shares of the medical equipment provider's stock worth $2,695,000 after acquiring an additional 547 shares during the last quarter. Rhumbline Advisers increased its position in shares of BioLife Solutions by 0.7% during the 1st quarter. Rhumbline Advisers now owns 83,227 shares of the medical equipment provider's stock valued at $1,901,000 after purchasing an additional 566 shares during the last quarter. GAMMA Investing LLC increased its position in shares of BioLife Solutions by 18.6% during the 1st quarter. GAMMA Investing LLC now owns 4,223 shares of the medical equipment provider's stock valued at $96,000 after purchasing an additional 663 shares during the last quarter. Finally, 1620 Investment Advisors Inc. increased its position in shares of BioLife Solutions by 41.7% during the 4th quarter. 1620 Investment Advisors Inc. now owns 2,295 shares of the medical equipment provider's stock valued at $60,000 after purchasing an additional 675 shares during the last quarter. Institutional investors own 93.24% of the company's stock.
BioLife Solutions Company Profile
(
Get Free Report)
BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
